Business Wire

TX-K2VIEW

11.8.2020 14:02:34 CEST | Business Wire | Press release

Share
K2View Raises $28 Million to Accelerate Rapid Expansion in the DataOps Market

K2View , a leading provider of real-time DataOps solutions, today announced its $28 million funding round, which will accelerate the company’s growth and expansion in the emerging DataOps market.

Forestay Capital led the round along with funding from Genesis Partners. It comes on the heels of rapid growth that saw over 75 percent CAGR in revenue, with a strong first half of 2020. This investment will be used to support the company’s go-to-market strategy as it continues its expansion in markets ripe for transformation with DataOps, such as telecom, financial services, healthcare, insurance, logistics and more.

“The fastest method to achieve true agility and exceptional customer experience is moving away from 30-plus years of application-driven enterprise into the data-driven enterprise. This is a critical component for digital transformation and a massive opportunity for us,” said Achi Rotem, CEO and co-founder of K2View. “As we look to the next stage of our growth, our vision is to continue helping companies unlock their potential by providing a faster, better and more cost-effective way to access and control data. To achieve funding of this size in the midst of a worldwide pandemic further proves our business potential. Forestay Capital and Genesis Partners share our vision for the future and are natural partners in helping us accelerate our growth.”

Data, an enterprise’s biggest asset, is siloed in hundreds of different applications and stored in different locations, technologies and structures. In this IT environment, enterprises cannot move fast and provide good customer experience at the same time. K2View’s patented approach and unique architecture deliver the data that enterprises need, exactly how and when they need it —all in real time. Since the launch of its platform in 2015, K2View has proven its vision and technology while helping some of the world’s largest companies tackle complex data challenges.

The platform provides the right data to the right person at the right time in just milliseconds and enables enterprises to operationalize all of their data and get holistic access to what matters the most to their business, while reducing time-to-market from months to weeks.

Changing economic conditions create even greater pressure for IT teams to do more with substantially fewer resources. K2View places efficient, elegant solutions into the hands of its users, delivering in weeks what would take months or years with traditional data management techniques. This helps companies reduce costs substantially while accelerating innovation with challenging use cases such as test data management, customer data hubs and compliance with data privacy regulations.

“As companies undergo digital transformation to adapt to a changing global economy and regulatory environment, K2View’s disruptive technology is transforming the use of data to accelerate business innovation,” said Frederic Wohlwend, Managing Partner at Forestay Capital. “We’re thrilled to partner with this talented and visionary team in their next growth journey and scale the business across the globe to help organizations tackle their most complex data challenges.”

“K2View’s patented solution helps enterprises quickly and cost-effectively achieve a 360-degree, real-time view of data—a challenge that has held back the innovation of enterprise IT,” said Gary Gannot, Managing Partner at Genesis Partners. “The DataOps market has unlimited opportunity and growth potential, and K2View is poised to strengthen its position of leadership as it supports the next wave of market expansion.”

About K2View

K2View is a leading provider of advanced data fabric, data integration, and data delivery software that takes the promise of a 360-degree view of data to the next level. Its flagship solution, K2View Fabric, uses patented logical unit technology to enable quick, easy, and secure access and control to all of an organization’s data, no matter how many different systems and data sources it may have. K2View delivers real-time, holistic access and operational insights to whatever data matters most to organizations in any industry, right when they need it, accelerating transformations in customer experience, cloud enablement, operations, IT modernization, and risk and compliance. Learn more at www.k2view.com and follow us at@k2view .

About Forestay Capital

Founded in 2017, Forestay invests in the tech sector and is focused on innovative, revenue-generating technology companies, in Europe, Israel and the USA, that challenge established models and the status-quo, primarily through software and data. It is part of Waypoint Capital , chaired by Ernesto Bertarelli, which supports a broad portfolio of leading asset management and investment businesses. (www.forestaycapital.com )

About Genesis Partners

Genesis Partners is a leading Israeli venture capital firm with a strong track record and ties to the Israeli entrepreneurs' community and the global technology industry. Its team is composed of venture professionals with extensive experience in venture capital, capital markets, technology, operational management, and entrepreneurship. With over $600M under management, over 100 investments and 38 exits with a current aggregate market value of $22B, Genesis Partners now focuses on growth-stage investments in the information technology and digital transformation sectors. Genesis Partners was founded in 1996 by Eddy Shalev and Dr. Eyal Kishon and joined by Gary Gannot in 2000.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye